As the American College of Cardiology's annual meeting kicked off in Orlando Saturday, all eyes turned to Sanofi and Regeneron, who reported that their PCSK9 med Praluent reduced the risk of cardiovascular events by 15%—as well as all-cause mortality by 15%—in the outcomes trial Odyssey.Original Article
As Praluent cuts death risks by 15%, Sanofi, Regeneron plot new push to win over payers
